CONFIDENCE IN THE POSITIVE IMPACT OF AUBAGIO® (teriflunomide) IN THE REAL WORLD



High treatment satisfaction scores were seen across all TSQM domains in all patients and also in those who switched to AUBAGIO[®] (teriflunomide)^{1,2}



Adherence and persistence significantly better on AUBAGIO $^{\rm @}$ compared to dimethyl fumarate (DMF) and injectables $^{\rm 3}$



Real-world efficacy and safety of AUBAGIO® supports its clinical outcomes¹



NO significant difference between AUBAGIO[®] and dimethyl fumarate (DMF) on clinical efficacy outcomes⁴

PRESCRIBE AUBAGIO® TO TREAT RRMS NOW AND OVER THE LONG TERM

RRMS=relapsing-remitting multiple sclerosis; TSQM=Treatment Satisfaction Questionnaire for Medication.





PROVIDE POSITIVE, REAL-WORLD TREATMENT EXPERIENCES

High treatment satisfaction scores were seen across all TSQM* domains in all patients and in those who switched to AUBAGIO[®] (teriflunomide)^{1,2}

	TSQM DOMAINS	ALL PATIENTS ¹ (Mean Scores)		SWITCHERS ^{1†} (Mean Scores)	
R	GLOBAL SATISFACTION	72.3	68.2	53.4	69.7
	EFFECTIVENESS	67.1	66.3	58.4	68.5
	SIDE EFFECTS	88.4	84.1	65.2	84.8
14	CONVENIENCE	92.3	90.4	58.4	90.4
		Week 4	Week 48	Baseline	Week 48

*The TSQM consists of 14 questions across 4 domains assessing the effectiveness, side effects, convenience, and global satisfaction of medication over the previous 2–3 weeks or since patient's last use of medication.1 [†]All scores were statistically significant (P<0.0001 versus baseline for all domains).

Teri-PRO: Teriflunomide Patient-Reported Outcomes Trial

A prospective, global, multicentre, single-arm, open-label, Phase IV trial of 1000 patients with relapsing MS. Patients received a daily dose of AUBAGIO® 14 mg (n=928) or teriflunomide 7 mg (n=72). Primary end point was the Global Satisfaction score, as measured by the TSQM at Week 48. Patients could enter the study irrespective of previous disease-modifying therapy (DMT) use.

• For patients switching from fingolimod,[‡] significant improvement was seen in the convenience domain at Week 48



This is a promotional material developed by Sanofi. Prescribing information and adverse events reporting can be found at page 8

For patients switching from dimethyl fumarate (DMF), treatment satisfaction was significantly improved at Week 48 for all TSQM domains and was seen as early as 4 weeks (P<0.0001 for all domains)¹

TERI-PRO: TREATMENT SATISFACTION AT WEEK 481





High levels of patient treatment satisfaction may lead to improved adherence^{1,2,5}

NS=not significant.

These are real-world observational trials with all appropriate limitations associated with observational trials. No head-to-head, randomised, controlled trials comparing the efficacy of AUBAGIO® with these comparators in patients with RRMS have yet been conducted.¹

¹Based on the half-life of fingolimod, a 6-week interval without therapy is needed for clearance from the circulation, and a 1-to-2-month period is needed for lymphocytes to return to normal range following discontinuation of fingolimod. Starting AUBAGIO® during this interval will result in concomitant exposure to fingolimod. This may lead to an additive effect on the immune system; therefore, caution is indicated.⁶

(teriflunomide) tablets

REASSURANCE WITH BETTER ADHERENCE AND PERSISTENCE ON AUBAGIO® COMPARED TO **DIMETHYL FUMARATE (DMF) AND INJECTABLES³**

Real-world treatment adherence was high and rate of discontinuations from adverse events were low with AUBAGIO[®] (teriflunomide) in the Teri-PRO trial¹



of patients reporting >80% compliance¹

11% of patients discontinued treatment¹

Utilising the SNIIRAM (Système National de l'Information Inter-Régimes de l'Assurance Maladie) study base, naive patients ages 18+ starting first-line treatment were followed ≥ 16 months. A total of 10,240 patients were identified (3548 on AUBAGIO®, 3450 on dimethyl fumarate, and 3242 on injectables). The 3 treatment groups were significantly different in terms of sex ratio, age at treatment initiation, age at full coverage for long-term diseases (Affections de Longue Durée [ALD]) registration, ALD status <1 year, concomitant treatment with antidepressants, and anti-epileptics at first-line DMT initiation. Patients treated with AUBAGIO® were often older, more often male, and often had a longer MS duration than the other groups. These are real-world observational trials with all appropriate limitations associated with observational trials. No head-to-head, randomised, controlled trials comparing the efficacy of AUBAGIO® with these comparators in patients with RRMS have not yet been conducted.

This is a promotional material developed by Sanofi. Prescribing information and adverse events reporting can be found at page 8

Persistence to AUBAGIO[®] was higher at all time points versus dimethyl fumarate (DMF) and injectables (P<0.0001)³

• 90% of MS patients adhere to AUBAGIO® versus 87% to DMF and 81% to injectables³

1.0 -0.8 -0.6 -0.4 -0.2 -0.0 -Month 0 10 12 24 30 36 18 20 No. of patients: **AUBAGIO®** 3548 2958 2599 2200 1491 936 299 1921 1408 831 475 injectables 3242 2522 162 3450 2806 2417 2032 1507 696 367 dimethyl fumarate

PERSISTENCE VERSUS INJECTABLES AND DMF³

Better adherence may lead to improved long-term outcomes^{2,5}



REAL-WORLD EFFICACY OF AUBAGIO® SUPPORTS ITS CLINICAL EXPERIENCE¹

Disability did not progress in patients treated with AUBAGIO® (teriflunomide) over the entire Teri-PRO trial for both physician- or patient-reported measures¹

TERI-PRO: EDSS AND PDDS SCORES AT BASELINE AND WEEK 48¹





EDSS=Expanded Disability Status Scale.

Teri-PRO: Teriflunomide Patient-Reported Outcomes Trial

A prospective, global, multicentre, single-arm, open-label, Phase IV trial of 1000 patients with relapsing MS. Patients received a daily dose of AUBAGIO® 14 mg (n=928) or teriflunomide 7 mg (n=72). Primary end point was the Global Satisfaction score, as measured by the TSQM at Week 48. Patients could enter the study irrespective of previous DMT use.

TAURUS-MS: A non-interventional, prospective, longitudinal real-world trial of 1128 patients with RRMS conducted in 307 German sites. All patients received once-daily AUBAGIO® 14 mg during the observation period. The primary end point was frequency of steroid-dependent MS relapses during the observation period.⁷

Patients switching to AUBAGIO[®] experienced a significant reduction in relapses and stable disability worsening that was sustained over 24 months⁷

TAURUS-MS: IMPACT ON RELAPSES AND DISABILITY WORSENING^{7,8}





Rely on AUBAGIO® for real-world results



This is a promotional material developed by Sanofi. Prescribing information and adverse events reporting can be found at page 8

AUBAGIO PI – GB

Prescribing Information: AUBAGIO® 14 mg (teriflunomide) filmcoated tablets

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Each film-coated tablet contains 14 mg of teriflunomide.

Indication: AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS).

Dosage and administration: The treatment should be initiated and supervised by a physician experienced in the management of MS. In adults, the recommended dose of teriflunomide is 14 mg once daily. In paediatric patients (10 years of age and above), the recommended dose is 14mg once daily with body weight >40 kg. AUBAGIO should be taken orally and swallowed whole with some water. AUBAGIO can be taken with or without food. *Elderly* (≥ 65 years): AUBAGIO should be used with caution due to insufficient data on safety and efficacy. <u>Renal impairment</u>: No dose adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis. Hepatic impairment: No dose adjustment is necessary for patients with mild and moderate hepatic impairment. Paediatric: The safety and efficacy in children aged below 10 years have not been established. No data are available.

Contraindications: Hypersensitivity to the active ingredient or excipients. Patients with severe hepatic impairment (Child-Pugh class C). Pregnant women, or women of childbearing potential not using reliable contraception during treatment and thereafter as long as plasma levels are above 0.02 mg/l. Breastfeeding women. Pregnancy must be excluded before start of treatment. Patients with severe immunodeficiency states, e.g. AIDS. Significantly impaired bone marrow function or significant anaemia, leucopoenia, neutropenia or thrombocytopenia. Severe active infection until resolution. Severe renal impairment undergoing dialysis, because insufficient clinical experience is available in this patient group. Severe hypoproteinaemia, e.g. in nephrotic syndrome.

Warnings and precautions: Monitoring: Before starting treatment: blood pressure, alanine aminotransferase (ALT/SGPT), complete blood cell count (CBC) including differential white blood cell (WBC) and platelet count. Pregnancy should be excluded. During treatment the following should be monitored: blood pressure periodically. ALT/SGPT assessed at least every 4 weeks for the first 6 months of treatment and regularly thereafter. Consider additional monitoring when AUBAGIO is given in patients with pre-existing liver disorders. given with other potentially hepatotoxic drugs or as indicated by clinical symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. Liver enzymes should be assessed every 2 weeks during the first 6 months of treatment, and at least every 8 weeks thereafter for at least 2 years from initiation of treatment. For ALT (SGPT) elevations between 2-

and 3-fold the upper limit of normal, monitoring must be performed weekly. CBC should be performed based on clinical signs and symptoms. Accelerated elimination procedure (AEP): Without an AEP, it takes an average of 8 months to reach plasma concentrations less than 0.02 mg/l and may take up to 2 years. An AEP can be used at any time after discontinuation of teriflunomide. Hepatic effects: Elevations of liver enzymes have been observed in patients receiving teriflunomide. These elevations occurred mostly within the first 6 months of treatment. Cases of drug-induced liver injury (DILI) have been observed during treatment with teriflunomide, sometimes lifethreatening. Most cases of DILI occurred with time to onset of several weeks or several months after treatment initiation of teriflunomide, but DILI can also occur with prolonged use. The risk for liver enzyme increases and DILI with teriflunomide might be higher in patients with pre-existing liver disorder, concomitant treatment with other hepatotoxic drugs, and/or consumption of substantial quantities of alcohol. Patients should be closely monitored for signs and symptoms of liver injury. Teriflunomide therapy should be discontinued and accelerated elimination procedure considered if liver injury is suspected. If liver enzymes are confirmed as >3x ULN, teriflunomide therapy should be discontinued. In case of treatment discontinuation, liver tests should be pursued until normalisation of transaminase levels. Infections: Patients receiving AUBAGIO should be instructed to report symptoms of infections to a physician. Patients with active acute or chronic infections should not start treatment with AUBAGIO until the infection(s) is resolved. Patients tested positive in tuberculosis screening should be treated by standard medical practice prior to therapy. <u>Respiratory reactions</u>: Interstitial lung disease (ILD) as well as cases of pulmonary hypertension have been reported with teriflunomide in the post-marketing setting. The risk might be increased in patients with a history of ILD. Due to the potential risk of ILD, pulmonary symptoms, such as persistent cough and dysphoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. <u>Haematological effects</u>: A mean decrease of <15% from baseline affecting WBC counts have been observed. Obtain CBC including differential white blood cell count and platelets prior to initiation of treatment, thereafter CBC should be assessed as indicated by clinical signs and symptoms. Patients with pre-existing cytopenias may have a higher risk of haematological disorders. In cases of severe haematological reactions, including pancytopenia, AUBAGIO and all concomitant myelosuppressive treatment must be discontinued and the AEP be considered. <u>Skin reactions</u>: Cases of serious skin reactions, sometimes fatal, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with AUBAGIO. If skin and /or mucosal reactions (ulcerative stomatitis) are observed which raise the suspicion of severe generalised major skin reactions,

teriflunomide must be discontinued and an accelerated procedure initiated immediately. New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during the use of teriflunomide. Treatment withdrawal and initiation of an AEP may be considered. Peripheral neuropathy: Discontinuing AUBAGIO therapy and performing the AEP should be considered. Vaccination: Live attenuated vaccines should be avoided. Interference with determination of ionised calcium levels: The measurement of ionised calcium levels might show falsely decreased values under treatment with teriflunomide. The plausibility of observed values should be questioned and in case of doubtful measurements, it is recommended to determine the total albumin adjusted serum calcium concentration. Immunosuppressive/ Immunomodulating therapies: Co-administration with leflunomide is not recommended. Co-administration with antineoplastic or immunosuppressive therapies has not been evaluated. SWITCHING to/from AUBAGIO: No waiting period is required when initiating teriflunomide after interferon beta or glatiramer acetate. Due to the risk of concomitant immune effects for up to 2-3 months, caution is required when switching patients immediately from natalizumab to teriflunomide. To avoid concomitant immune effects when switching from fingolimod, 10-14 weeks is needed for lymphocytes to return to the normal range. If a decision is made to stop treatment with AUBAGIO, during the interval of 5 half-lives (approximately 3.5 months, although may be longer in some patients), starting other therapies will result in concomitant exposure to AUBAGIO. This may lead to an additive effect on the immune system and caution is, therefore, indicated. Paediatric population: Cases of pancreatitis have been observed. Clinical symptoms included abdominal pain, nausea and/or vomiting. Serum amylase and lipase were elevated in these patients. The time to onset ranged from a few months up to three years. Patients should be informed of the characteristic symptoms of pancreatitis. If pancreatitis is suspected, pancreatic enzymes and related laboratory parameters should be obtained. If pancreatitis is confirmed, teriflunomide should be discontinued and an accelerated elimination procedure should be initiated. Lactose: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product. Sodium: This medicine contains less than 1 mmol sodium (23 mg per tablet), that is to say essentially "sodium free". Interactions: Rifampicin and other known potent CYP and transporter inducers; medicinal products metabolised by CYP1A2 or CYP2C8: substrates of OAT3: substrates of BCRP and the OATP family, especially HMG-Co reductase inhibitors, should be used with caution during the treatment with teriflunomide. Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered. Co-administration with cholestyramine or activated charcoal is not recommended

unless an accelerated elimination is desired. Whilst the interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, it should be considered when selecting or adjusting oral contraceptive treatment. A 25% decrease in peak international normalised ratio (INR) was observed when teriflunomide was coadministered with warfarin as compared with warfarin alone. Close INR follow-up and monitoring is recommended. Pregnancy and lactation: Women of childbearing potential must use effective contraception during treatment and after treatment as long as teriflunomide plasma concentration is >0.02 mg/l. Female children and/or parents/caregivers of female children should be informed about the need to contact the treating physician once the female child under AUBAGIO treatment experiences menses. Counselling should be provided to the new patients of child-bearing potential about contraception and the potential risk to the foetus. Referral to a gynaecologist should be considered. Plans to stop or change contraception, or in the case of suspected pregnancy, patient must discontinue AUBAGIO and notify the physician immediately. In case of pregnancy, the physician and patient must discuss the risk to the pregnancy and the AEP. In women wishing to become pregnant, teriflunomide should be stopped and an AEP is recommended.

Please see SmPC for more details. Lactation is contraindicated. Adverse effects: Very common (≥1/10): Headache, diarrhoea, nausea, alopecia and ALT increase. Common (≥1/100 to <1/10): Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, pharyngitis, cystitis, gastroenteritis viral, oral herpes, tooth infection, laryngitis, tinea pedis, neutropenia, anaemia, mild allergic reactions, anxiety, paraesthesia, sciatica, carpal tunnel syndrome, palpitations, hypertension, pancreatitis in the paediatric population, upper abdominal pain, vomiting, toothache, Gammaglutamyltransferase increase, aspartate aminotransferase increase, rash, acne, musculoskeletal pain, myalgia, arthralgia, pollakiuria, menorrhagia, pain, asthenia, weight decrease, neutrophil count decrease, WBC decrease and blood creatine phosphokinase increase. Uncommon (≥1/1000 to <1/100): Severe infections including sepsis, mild thrombocytopenia (platelets <100G/l), hypersensitivity reactions (immediate or delayed) including anaphylaxis and angioedema, hyperaesthesia, neuralgia, peripheral neuropathy, interstitial lung disease, pancreatitis in the adult population, stomatitis, colitis, dyslipidaemia, nail disorders psoriasis (including pustular), severe skin reactions and post-traumatic pain. **Rare:** ($\geq 1/10,000$ to < 1/1,000): Acute hepatitis. Frequency not known: Pulmonary hypertension,

drug-induced liver injury (DILI. Please see SPC for full details. Legal Classification: POM. List Price: GB: £1037.84 (28x tablets). Marketing authorisation number: PLGB 04425/0819. Marketing authorisation holder: Aventis Pharma Ltd, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. For more information please contact: Medical Information, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. Or uk-medicalinformation@sanofi.com. Date of Preparation: December 2023.

Adverse events should be reported. Reporting forms and information can be found at: In the UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902314. Alternatively, send via email to <u>UK-drugsafety@sanofi.com</u>

References: 1. Coyle PK, Khatri B, Edwards KR, et al; for the Teri-PRO Trial Group. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017:17:107-115. 2. Covle PK, Khatri B, Edwards KR, et al: for the Teri-PRO Trial Group. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies; results from the global phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 2018;26:211-218. 3. Vermersch P, Suchet L, Colamarino R, Laurendeau, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsingremitting multiple sclerosis using the French nationwide health claims database from 2014-2017. Mult Scler Relat Disord. 2020; 19:46:102521. doi: 10.1016/j.msard.2020.102521. 4. Zivadinov R, Bergsland N, Carl E, et al. Effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case-control pilot study. J Clin Med. 2019;8(3):344. doi:10.3390/jcm8030344. 5. Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9(4):250-263. 6. AUBAGIO (teriflunomide) Great Britain Summary of Product Characteristics (last date of revision: December 2021). 7. Kallmann B, Tiel-Wilck K, Kullmann JS, et al; on behalf of the TAURUS-MS study group. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;27:12:1756286419835077. doi: 10.1177/1756286419835077. 8. Rosenkranz T, Kallmann B, Engelmann U, et al; on behalf of the TAURUS-MS I study team. Efficacy and safety of teriflunomide in patients switching from other DMTs in the real-world TAURUS-MS I study. Poster presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 11-13, 1019; Stockholm, Sweden. Poster EP1549 9. Laplaud D, Casey R, Barbin L, et al; on behalf of the SFSEP and OFSEP groups. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635-e646. doi: 10.1212/WNL.00000000007938.



This is a promotional material developed by Sanofi. Prescribing information and adverse events reporting can be found at page 8

AUBAGIO[®] HAS COMPARABLE EFFICACY VERSUS DIMETHYL FUMARATE (DMF) IN THE REAL WORLD^{4,9}



1770 patients followed prospectively in the Observatoire Français de la Sclérose En Plaques (OFSEP) with RRMS (713 on TRF and 1057 on DMF) with an available baseline brain MRI were included in intention to treat. Primary end point was the proportion of patients with at least 1 relapse at 1 year post initiation. This is a real world observational trial with all appropriate limitations associated with observational trials. No head-to-head, randomised, controlled trials comparing the efficacy of AUBAGIO® (teriflunomide) with these comparators in patients with RRMS have not yet been conducted.^{4,9}

Take comfort in the real-world efficacy of AUBAGIO®

This is a promotional material developed by Sanofi. Prescribing information and adverse events reporting can be found at page 8



©2021 Genzyme Corporation. All rights reserved. MAT-XU-2202430-V2.0-December 2023 Sanofi and AUBAGIO are registered trademarks of Sanofi.

